AU2020275304B2 - Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions - Google Patents
Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions Download PDFInfo
- Publication number
- AU2020275304B2 AU2020275304B2 AU2020275304A AU2020275304A AU2020275304B2 AU 2020275304 B2 AU2020275304 B2 AU 2020275304B2 AU 2020275304 A AU2020275304 A AU 2020275304A AU 2020275304 A AU2020275304 A AU 2020275304A AU 2020275304 B2 AU2020275304 B2 AU 2020275304B2
- Authority
- AU
- Australia
- Prior art keywords
- nmr
- mmol
- mhz
- ripk3
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848719P | 2019-05-16 | 2019-05-16 | |
| US201962848648P | 2019-05-16 | 2019-05-16 | |
| US62/848,719 | 2019-05-16 | ||
| US62/848,648 | 2019-05-16 | ||
| PCT/US2020/032784 WO2020232190A1 (en) | 2019-05-16 | 2020-05-14 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020275304A1 AU2020275304A1 (en) | 2021-12-16 |
| AU2020275304B2 true AU2020275304B2 (en) | 2025-01-23 |
Family
ID=70919255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020275304A Active AU2020275304B2 (en) | 2019-05-16 | 2020-05-14 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12516055B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4480485A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7546603B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020275304B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3137869A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020232190A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213219A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
| CA3137869A1 (en) * | 2019-05-16 | 2020-11-19 | Gregory Cuny | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
| CN113072471B (zh) * | 2021-03-02 | 2022-09-16 | 四川美大康华康药业有限公司 | 一种利非司特中间体及其制备方法 |
| WO2024097805A1 (en) * | 2022-11-01 | 2024-05-10 | Trustees Of Tufts College | Mixed lineage kinase domain like pseudokinase (mlkl) activators |
| WO2024199388A1 (zh) * | 2023-03-29 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
| CN121197168A (zh) * | 2025-11-20 | 2025-12-26 | 中山大学 | UH15-38在制备防治PEDV-PoRVA共感染药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213219A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| AU742999B2 (en) | 1997-08-20 | 2002-01-17 | Warner-Lambert Company | Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
| SK10772002A3 (sk) * | 2000-01-27 | 2004-01-08 | Warner-Lambert Company | Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení |
| WO2014031571A1 (en) | 2012-08-21 | 2014-02-27 | Icahn School Of Medicine At Mount Sinai | Treatment of viral infections |
| WO2015179436A1 (en) * | 2014-05-19 | 2015-11-26 | Sanford-Burnham Medical Research Institute | Inflammation therapy using mekk3 inhibitors or blocking peptides |
| CA3137869A1 (en) | 2019-05-16 | 2020-11-19 | Gregory Cuny | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
-
2020
- 2020-05-14 CA CA3137869A patent/CA3137869A1/en active Pending
- 2020-05-14 US US17/595,406 patent/US12516055B2/en active Active
- 2020-05-14 EP EP24191377.1A patent/EP4480485A3/en active Pending
- 2020-05-14 AU AU2020275304A patent/AU2020275304B2/en active Active
- 2020-05-14 EP EP20729566.8A patent/EP3968991B1/en active Active
- 2020-05-14 JP JP2021568650A patent/JP7546603B2/ja active Active
- 2020-05-14 WO PCT/US2020/032784 patent/WO2020232190A1/en not_active Ceased
-
2024
- 2024-08-27 JP JP2024145040A patent/JP7897681B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213219A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3968991A1 (en) | 2022-03-23 |
| US20220194937A1 (en) | 2022-06-23 |
| WO2020232190A1 (en) | 2020-11-19 |
| AU2020275304A1 (en) | 2021-12-16 |
| EP4480485A2 (en) | 2024-12-25 |
| EP3968991C0 (en) | 2024-07-31 |
| EP3968991B1 (en) | 2024-07-31 |
| JP2022533182A (ja) | 2022-07-21 |
| US12516055B2 (en) | 2026-01-06 |
| JP2024170457A (ja) | 2024-12-10 |
| JP7546603B2 (ja) | 2024-09-06 |
| EP4480485A3 (en) | 2025-02-26 |
| JP7897681B2 (ja) | 2026-07-30 |
| CA3137869A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12516055B2 (en) | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | |
| CN114555588B (zh) | 作为axl抑制剂的喹唑啉类化合物 | |
| CA3203205A1 (en) | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer | |
| US10087195B2 (en) | Certain protein kinase inhibitors | |
| TWI393566B (zh) | 作為週期素依賴性激酶之新穎吡唑并嘧啶 | |
| AU2017268536B2 (en) | Novel compounds and compositions for inhibition of FASN | |
| AU2025237955A1 (en) | KRAS G12C inhibitors and methods of using the same | |
| KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
| CA2681162C (en) | Benzyl and pyridine derivatives as modulators of hedgehog pathway | |
| CN108794411B (zh) | 某些化学实体、组合物及方法 | |
| CA2968633C (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
| US9024021B2 (en) | Diarylacetylene hydrazide containing tyrosine kinase inhibitors | |
| JP2023512038A (ja) | 化合物及びその使用 | |
| US20110212053A1 (en) | Phosphatidylinositol 3 kinase inhibitors | |
| Kankanala et al. | Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2, 4-diones as inhibitors of HIV reverse transcriptase-associated RNase H | |
| TW201906848A (zh) | 化學化合物 | |
| US12624032B2 (en) | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | |
| WO2014079232A1 (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
| AU2004283093A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| KR20070027723A (ko) | 4,6-이치환된 피리미딘 및 단백질 키나제 억제제로서의이의 용도 | |
| CN106536482A (zh) | 具有抗hiv作用的苯基和叔丁基乙酸取代的吡啶酮 | |
| CN112851667B (zh) | 含氮并杂环类化合物及其药用组合物和应用 | |
| CN114981256B (zh) | 干扰素基因刺激物sting的单环激动剂 | |
| Jin et al. | Pyrrolo [2, 3-b] pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma | |
| KR102288434B1 (ko) | 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |